This Month in Psychopharmacology

Novel M1/M4 Agonist Demonstrates Phase 2 Efficacy in Schizophrenia

An oral, extended-release, fixed-dose combination of betovumeline, ...

Read More

FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

The U.S. Food and Drug Administration has approved centanafadine, a...

Read More

Tardive Dyskinesia Burden Extends Beyond the Patient to Caregivers

Although tardive dyskinesia is often assessed as a patient-level ad...

Read More

Sleep Complaints May Signal Alzheimer’s Risk in Genetically Vulnerable Older Women

Sleep disturbance is increasingly viewed as a potentially modifiabl...

Read More

Low-Dose Buprenorphine May Enhance Ketamine's Antisuicidal Effects in Major Depression

Suicidal ideation in major depressive disorder (MDD) is a major cli...

Read More

The Association Between Omega-3 Supplementation and Cognitive Decline in Older Adults

In older adults, cognitive training can facilitate long-term improv...

Read More

Supporting Better Mental Health Outcomes Through Inclusive Care

June is Pride Month and it’s important to understand the barriers t...

Read More

PTSD Is Increasing Among US Veterans: Updated National Data Highlight the Need for Trauma-Informed Assessment

Posttraumatic stress disorder (PTSD) remains one of the most clinic...

Read More

A Novel D2/D3/5-HT7 Antagonist Shows Promise in Acute Schizophrenia

Amisulpride is a benzamide-based antipsychotic that is not approved...

Read More

Magnetic Seizure Therapy vs. Electroconvulsive Therapy for Bipolar Depression

ECT is among the most effective treatments for treatment-resistant ...

Read More

Poor Mood Response to Oral Contraceptives Linked to Higher Risk of Peripartum and Premenstrual Depression

Depressive episodes occurring at times of reproductive hormone chan...

Read More

Mirtazapine Demonstrates Efficacy in Routine Care for Methamphetamine Use Disorder

Methamphetamine use disorder affects about 7.4 million people world...

Read More